PMID- 34530784
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20220531
IS  - 1471-2474 (Electronic)
IS  - 1471-2474 (Linking)
VI  - 22
IP  - 1
DP  - 2021 Sep 16
TI  - Safety and efficacy of a single intra-articular injection of hyaluronic acid in 
      osteoarthritis of the hip: a case series of 87 patients.
PG  - 797
LID - 10.1186/s12891-021-04672-0 [doi]
LID - 797
AB  - BACKGROUND: Osteoarthritis (OA) is the most prevalent form of joint disease and 
      commonly affects the hip. Hip OA is associated with a high socioeconomic burden. 
      Intra-articular hyaluronic acid (HA) injection may be of benefit but quality 
      evidence for HA use in hip OA is lacking. The purpose of this study was to assess 
      the safety and efficacy of ultrasound guided injection of a high molecular 
      weight, non-animal derived, stabilised HA (NASHA) in patients with mild to 
      moderate hip OA. METHODS: This single site study is an analysis of prospectively 
      collected outcome data for 87 consecutive patients over a 2-year period who 
      received a single HA (Durolane) injection for symptomatic hip OA. Inclusion 
      criteria were male or female patients over 18-years of age with mild to moderate 
      hip OA on x-ray. Patients with severe hip OA were excluded. The primary outcome 
      measure was a modified Harris Hip Score (mHHS) questionnaire at baseline and 
      6-weeks with a minimal clinically important difference (MCID) of 10 points. All 
      adverse events were recorded and assessed. RESULTS: Data from 87 patients, 49 
      women and 38 men with mean age of 54 (SD = 10.8) were analysed. At baseline, mean 
      mHHS was 58.47 (SD 14.31). At the 6 week follow up, mean mHHS improved to 71.30 
      (SD 16.46), a difference of 12.83 (p < 0.01). This was greater than the MCID of 
      10. No significant adverse events were encountered. Five patients reported 
      short-lived injection site pain. CONCLUSION: A single injection of HA (NASHA) in 
      the setting of hip joint OA was both safe and efficacious in this 87 patient 
      cohort. Improvement in pain and function as measured with mHHS was statistically 
      significant and reached the MCID of 10. TRIAL REGISTRATION: The study was 
      retrospectively registered on the 1st of February 2021 in the Australian New 
      Zealand Clinical Trials Registry with registry number ACTRN12621000098831 . All 
      research was performed in accordance with the Declaration of Helsinki.
CI  - (c) 2021. The Author(s).
FAU - Long, David M
AU  - Long DM
AD  - Olympic Park Sports Medicine Centre, 60 Olympic Blvd, Melbourne, 3004, Australia.
AD  - School of Medicine, Deakin University, Little Malop St, Geelong, Victoria, 3220, 
      Australia.
FAU - Fitzpatrick, Jane
AU  - Fitzpatrick J
AD  - Centre for Health and Exercise Sports Medicine, Faculty of Medicine, Dentistry 
      and Health Science, University of Melbourne, Level 7, Alan Gilbert Building, 161 
      Barry Street, Parkville, Victoria, 3010, Australia. 
      jane.fitzpatrick@unimelb.edu.au.
AD  - Joint Health Institute, Malvern, Victoria, 3144, Australia. 
      jane.fitzpatrick@unimelb.edu.au.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20210916
PL  - England
TA  - BMC Musculoskelet Disord
JT  - BMC musculoskeletal disorders
JID - 100968565
RN  - 9004-61-9 (Hyaluronic Acid)
SB  - IM
MH  - Adult
MH  - Australia
MH  - Female
MH  - Humans
MH  - Hyaluronic Acid/adverse effects
MH  - Injections, Intra-Articular/adverse effects
MH  - Male
MH  - Middle Aged
MH  - *Osteoarthritis, Hip/diagnostic imaging/drug therapy
MH  - *Osteoarthritis, Knee/drug therapy
MH  - Treatment Outcome
PMC - PMC8447787
OTO - NOTNLM
OT  - Durolane
OT  - Hip joint
OT  - Modified Harris hip score
OT  - NASHA
COIS- Dr. David Long has no competing interests to declare. A/Prof Jane Fitzpatrick has 
      previously been on the medical advisory board for Bioventus Global.
EDAT- 2021/09/18 06:00
MHDA- 2021/09/21 06:00
PMCR- 2021/09/16
CRDT- 2021/09/17 05:43
PHST- 2021/03/11 00:00 [received]
PHST- 2021/09/01 00:00 [accepted]
PHST- 2021/09/17 05:43 [entrez]
PHST- 2021/09/18 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2021/09/16 00:00 [pmc-release]
AID - 10.1186/s12891-021-04672-0 [pii]
AID - 4672 [pii]
AID - 10.1186/s12891-021-04672-0 [doi]
PST - epublish
SO  - BMC Musculoskelet Disord. 2021 Sep 16;22(1):797. doi: 10.1186/s12891-021-04672-0.